Pharmaceutical Technology on MSN

FDA halts uniQure’s plans for Huntington’s disease gene therapy

"FDA halts uniQure’s plans for Huntington’s disease gene therapy" was originally created and published by Pharmaceutical ...
BioSpace

4 Huntington’s Therapies Chasing UniQure

Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at ...
Stocktwits on MSN

Huntington Bancshares To Buy Cadence Bank In $7.4 Billion All-Stock Deal: Report

Huntington CEO Steve Steinour told The Wall Street Journal that the acquisition represents an “important next stage” for the ...

Huntington strikes $7.4 billion deal to expand in the South

Huntington Bancshares Inc. agreed to buy Cadence Bank for $7.4 billion, the Ohio bank’s second major acquisition this year to ...

A Closer Look at uniQure (QURE) Valuation Following FDA Shift on Huntington’s Gene Therapy Data

Qure (QURE) shares have taken a hit after the FDA withdrew support for using Phase I/II data from its AMT-130 Huntington's disease gene therapy in a key regulatory submission. This unexpected shift ...
The Conversation

A new treatment for Huntington’s disease is genuinely promising – but here’s why we still need caution

Bryce Vissel does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...